STOCK TITAN

Sarepta Therapeutics, (SRPT) Financials

SRPT NASDAQ
Trailing 12 months to September 30, 2026
Revenue $2.0B -18.9% YoY
Net Income -$114.6M n/m YoY
EPS (Diluted) -$1.37 n/m YoY
Free Cash Flow $176.4M n/m YoY
Market Cap $1.6B as of Nov 17, 2026
Price / Sales 0.8x on $2.0B revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 1.0x on $1.5B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SRPT SEC filings page.

Sarepta Therapeutics,, Inc. (SRPT) reported $2.0B in revenue over the twelve months to Sep 30, 2026, down 18.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SRPT FY2025

Revenue kept growing in FY2025, but a major R&D increase reversed profit and left cash flow negative.

FY2024 paired net income of $235M with operating cash flow of -$206M, so accounting profit did not translate into cash. FY2025 then posted a net loss of $713M while operating cash flow was -$205M, showing the earnings reversal was much larger than the cash-flow change.

R&D rose 89.2% to $1.5B in FY2025, making development spending the dominant cost pressure. Its 69.2% revenue share coincided with a 43.3-percentage-point operating-margin drop, despite continued sales growth.

Current ratio fell from 4.2x to 2.3x in FY2025, making near-term obligations more prominent. Long-term debt fell 27.1% while debt-to-equity was 0.7x, so the shift points more to liability timing than added leverage; the supplied liquidity measure equaled 54.9 months of latest annual reported outflow.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 42 / 100
Financial Health Score 42/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Sarepta Therapeutics,, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
21

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Sarepta Therapeutics,, Inc. scores 21/100 on it among other operating companies.

Growth
90

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Sarepta Therapeutics,, Inc. scores 90/100 on it among other operating companies.

Leverage
46

Sarepta Therapeutics,, Inc. carried $0.73 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2025, a debt-to-equity ratio of 0.73. With no positive EBITDA in fiscal year 2025, Sarepta Therapeutics,, Inc. is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 46/100 among other operating companies measured the same way.

Liquidity
67

Sarepta Therapeutics,, Inc. held $2.32 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 2.32. Liquidity ranks operating companies on that ratio, and Sarepta Therapeutics,, Inc. scores 67/100 among other operating companies.

Cash Flow
9

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Sarepta Therapeutics,, Inc. scores 9/100 on it among other operating companies.

Returns
21

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Sarepta Therapeutics,, Inc. scores 21/100 on it among other operating companies.

Altman Z-Score Distress
-1.12

Sarepta Therapeutics,, Inc. scores -1.12, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $4.9B against total assets of $3.3B. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
3/8

Sarepta Therapeutics,, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality No Cash Backing
N/A

Sarepta Therapeutics,, Inc. reported a net loss of $713.4M while operations used $205.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Sarepta Therapeutics,, Inc. reported an operating loss of $699.8M against $38.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$381.4M
YoY-4.5%
QoQ-5.0%
5Y CAGR+15.0%

Sarepta Therapeutics,, Inc. generated $381.4M in revenue in Q3 2026. This represents a decrease of 4.5% from the same quarter a year earlier. Against the prior quarter it is down 5.0%.

EBITDA
-$3.1M
YoYn/m
QoQ-113.2%

Sarepta Therapeutics,, Inc.'s EBITDA was -$3.1M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 113.2%.

Net Income
-$28.5M
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Sarepta Therapeutics,, Inc. reported a net loss of $28.5M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.27
YoYn/m
QoQn/m

Sarepta Therapeutics,, Inc. earned -$0.27 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
$57.0M
YoYn/m
QoQ-71.0%
5Y CAGRn/m
10Y CAGRn/m

Sarepta Therapeutics,, Inc. generated $57.0M in free cash flow in Q3 2026, representing cash available after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 71.0%.

Cash & Debt
$472.8M
YoY-22.9%
QoQ-17.2%
5Y CAGR-21.6%
10Y CAGR+1.8%

Sarepta Therapeutics,, Inc. held $472.8M in cash against $857.4M in long-term debt as of Q3 2026.

Shares Outstanding
107M
YoY+2.3%
QoQ+1.5%

Sarepta Therapeutics,, Inc. had 107M shares outstanding in Q3 2026. This represents an increase of 2.3% from the same quarter a year earlier. Against the prior quarter it is up 1.5%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Operating Margin
-2.4%
YoY+23.5pp
QoQ-5.7pp

Sarepta Therapeutics,, Inc.'s operating margin was -2.4% in Q3 2026, reflecting core business profitability. This is up 23.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.7 percentage points.

Net Margin
-7.5%
YoY+5.2pp
QoQ-6.2pp
5Y change+18.0pp

Sarepta Therapeutics,, Inc.'s net profit margin was -7.5% in Q3 2026, showing the share of revenue converted to profit. This is up 5.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.2 percentage points.

Return on Equity
-1.9%
YoY+1.5pp
QoQ-1.5pp
5Y change+8.4pp
10Y change+12.0pp

Sarepta Therapeutics,, Inc.'s quarterly ROE was -1.9% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 1.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.5 percentage points.

Gross Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$82.5M
YoY-62.3%
QoQ-9.5%

Sarepta Therapeutics,, Inc. invested $82.5M in research and development in Q3 2026. This represents a decrease of 62.3% from the same quarter a year earlier. Against the prior quarter it is down 9.5%.

Capital Expenditures
$2.9M
YoY-87.2%
QoQ+428.6%
5Y CAGR-20.5%
10Y CAGR+13.3%

Sarepta Therapeutics,, Inc. invested $2.9M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 87.2% from the same quarter a year earlier. Against the prior quarter it is up 428.6%.

Share Buybacks

Not reported for Q3 2026.

SRPT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SRPT quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$381.4M-4.5%$401.3M-34.3%$730.8M-1.9%$442.9M-32.7%$399.4M-14.5%$611.1M+68.4%$744.9M+80.2%$658.4M+65.9%
Gross ProfitN/AN/AN/A-$29.1M-105.8%$219.3M-35.1%$360.6M+14.1%$474.0M+53.4%$505.9M
R&D Expenses$82.5M-62.3%$91.3M-55.4%$154.0M-80.1%N/A$218.9M-2.5%$204.4M+13.7%$773.4M+286.0%N/A
SG&A Expenses$118.6M+29.1%$107.6M-22.0%$109.0M-18.5%N/A$91.9M-28.3%$137.9M-0.6%$133.6M+5.2%N/A
Operating Income-$9.0Mn/m$13.3M-88.5%$358.4Mn/mN/A-$103.4M-565.8%$115.6Mn/m-$300.4M-960.6%N/A
EBITDA-$3.1Mn/m$23.7M-81.3%$369.0Mn/mN/A-$84.9M-365.4%$126.4M+1476.7%-$290.4M-765.3%N/A
Interest Expense$21.6M+128.5%-$21.5Mn/m-$21.7Mn/mN/A$9.5M+92.4%-$5.2M-208.2%-$4.5Mn/mN/A
Income Tax$2.7Mn/m$3.1Mn/m$12.2M-80.9%N/A-$14.1M-3670.1%-$43.3M-707.8%$64.0M+1100.8%N/A
Net Income-$28.5Mn/m-$4.9M-102.5%$331.0Mn/m-$412.2M-359.2%-$50.6M-250.5%$196.9M+2947.9%-$447.5M-1339.0%$159.0M+248.4%
EPS (Basic)-$0.27n/m-$0.05-102.5%$3.15n/m-$3.93-338.2%-$0.50-242.9%$2.01+2771.4%-$4.60-1310.5%$1.65
EPS (Diluted)-$0.27n/m-$0.05-102.6%$2.88n/m-$3.93-362.0%-$0.50-247.1%$1.89+2600.0%-$4.60-1343.2%$1.50
Diluted Shares (Avg)106M+5.7%105M-1.1%122M+25.2%N/A100M-0.2%107M+7.5%97M-1.8%N/A

Not reported in any period shown, so not listed: Cost of Revenue.

SRPT Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SRPT quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'25FilingQ1'25FilingQ4'2410-K
Total Assets$3.2B-9.4%$3.2B-13.4%$3.2B-8.3%$3.3B-15.5%$3.5B-3.0%$3.7B+7.5%$3.5B+7.5%$4.0B+21.4%
Current Assets$2.3B-16.5%$2.2B-16.3%$2.3B-5.0%$2.5B-17.4%$2.7B+1.4%$2.7B-1.0%$2.4B-1.3%$3.1B+19.2%
Cash & Equivalents$472.8M-22.9%$571.1M+11.9%$464.4M+92.8%$801.3M-27.4%$613.1M+209.9%$510.6M+33.1%$240.9M-43.6%$1.1B+157.5%
Short-Term Investments$406.0M+70.7%$217.3M-24.9%$188.7M-33.0%$138.4M-45.0%$237.9M-76.2%$289.5M-73.1%$281.9M-70.7%$251.8M-79.8%
Inventory$876.1M-18.7%$904.3M-9.0%$1.0B+6.3%$914.7M+22.0%$1.1B+90.3%$994.0M+104.6%$941.4M+152.0%$750.0M+132.3%
Accounts Receivable$369.2M-6.7%$376.8M-28.5%$394.8M-40.1%$398.2M-33.8%$395.7M-8.9%$527.3M+46.5%$659.4M+74.1%$602.0M+50.4%
Long-Term Investments$108.8M+10363.0%$145.4M+320.1%$81.9M-24.9%$1.0M-99.2%$1.0M-99.4%$34.6Mn/m$109.1M+221.9%$133.2M-68.9%
Total Liabilities$1.6B-24.7%$1.7B-28.5%$1.7B-27.9%$2.2B-9.3%$2.2B-8.6%$2.3B-1.1%$2.3B+2.6%$2.4B+1.3%
Current Liabilities$656.4M-28.8%$502.9M-45.3%$499.2M-17.6%$1.1B+49.7%$921.4M+31.7%$919.9M+33.6%$605.6M-0.5%$731.7M+11.9%
Non-Current Liabilities$980.9M-21.6%$1.2B-17.4%$1.2B-31.6%$1.1B-34.6%$1.3B-25.5%$1.4B-15.4%$1.7B+3.8%$1.7B-2.7%
Long-Term Debt$857.4M+510.2%$847.6M$838.2M$829.0M-27.1%$140.5M-88.6%N/AN/A$1.1B-8.1%
Total Equity$1.5B+2.1%$1.5B+8.8%$1.5B+26.5%$1.1B-25.3%$1.5B+22.6%$1.4B+30.4%$1.2B+23.8%$1.5B+77.8%
Retained Earnings-$4.6Bn/m-$4.6Bn/m-$4.5Bn/m-$4.9Bn/m-$4.6Bn/m-$4.5Bn/m-$4.7Bn/m-$4.2Bn/m

Not reported in any period shown, so not listed: Goodwill.

SRPT Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SRPT quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$60.0Mn/m$197.1M-24.6%-$202.7Mn/m$131.2M+42.5%-$14.6Mn/m$261.3M+1649.0%-$583.4Mn/m$92.0Mn/m
Depreciation & Amortization$5.9M-68.0%$10.4M-4.0%$10.6M+6.2%$5.3M-49.8%$18.4M+88.2%$10.8M+24.3%$10.0M+14.1%$10.5M-8.1%
Stock-Based Compensation$26.7M+79.2%$24.5M-33.8%$29.4M-29.0%N/A$14.9M-65.7%$37.0M-26.7%$41.4M+1.8%N/A
Capital Expenditures$2.9M-87.2%$555K-98.3%$2.1M-95.2%$3.6M-90.6%$22.9M-38.5%$31.8M+9.0%$43.7M+34.5%$38.1M+100.0%
Free Cash Flow$57.0Mn/m$196.5M-14.4%-$204.8Mn/m$127.6M+136.5%-$37.5Mn/m$229.5Mn/m-$627.1Mn/m$54.0Mn/m
Investing Cash Flow-$158.4M-168.1%-$93.4M-389.9%-$134.4Mn/m$96.2M-87.4%$232.4Mn/m$32.2Mn/m-$291.2M-233.1%$764.1Mn/m
Financing Cash Flow$0n/m$0n/m$241K-98.1%-$39.2M-180.0%-$117.8M-956.2%-$23.8M-159.7%$12.5M-43.7%$49.0M+2421.4%
Share BuybacksN/AN/AN/A$0n/m$0n/mN/AN/A$0

Not reported in any period shown, so not listed: Dividends Paid.

SRPT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SRPT quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross MarginN/AN/AN/A-6.6%-83.4pp54.9%-17.5pp59.0%-28.1pp63.6%-11.1pp76.8%
Operating Margin-2.4%+23.5pp3.3%-15.6pp49.0%+89.4ppN/A-25.9%-30.6pp18.9%+19.1pp-40.3%-48.8ppN/A
Net Margin-7.5%+5.2pp-1.2%-33.4pp45.3%+105.4pp-93.1%-117.2pp-12.7%-19.9pp32.2%+30.4pp-60.1%-68.8pp24.2%+12.7pp
Return on Equity-1.9%+1.5pp-0.3%-14.3pp22.0%+59.6pp-36.1%-46.6pp-3.4%-6.1pp14.0%+13.4pp-37.6%-41.4pp10.4%+5.1pp
Return on Assets-0.9%+0.6pp-0.1%-5.5pp10.4%+23.3pp-12.3%-16.3pp-1.5%-2.4pp5.3%+5.2pp-12.9%-14.0pp4.0%+2.6pp
Current Ratio3.46+0.5x4.42+1.5x4.63+0.6x2.32-1.9x2.95-0.9x2.89-1.0x4.020.0x4.20+0.3x
Debt-to-Equity0.56+0.5x0.550.560.730.0x0.09-0.9xN/AN/A0.74-0.7x
Liabilities-to-Equity1.07-0.4x1.09-0.6x1.11-0.8x1.94+0.3x1.45-0.5x1.65-0.5x1.95-0.4x1.59-1.2x
Asset Turnover0.120.0x0.130.0x0.230.0x0.130.0x0.110.0x0.17+0.1x0.21+0.1x0.170.0x
FCF Margin15.0%+24.3pp49.0%+11.4pp-28.0%+56.2pp28.8%+20.6pp-9.4%+13.7pp37.6%+41.5pp-84.2%-17.8pp8.2%+26.8pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Sarepta Therapeutics,, Inc. SRPT FY2025 $2.2B -$713.4M -32.5% $1.6B 42/100
uniQure N.V. QURE FY2025 $16.1M -$199.0M N/A $1.5B 58/100
Ultragenyx Pharmaceutical Inc. RARE FY2025 $673.0M -$575.0M -85.4% $1.7B 58/100
Zenas BioPharma, Inc. ZBIO FY2025 $10.0M -$377.7M N/A $1.9B 36/100
Zymeworks Inc. ZYME FY2025 $106.0M -$81.1M -76.6% $1.8B 79/100
Stoke Therapeutics, Inc. STOK FY2025 $184.4M -$6.9M -3.7% $1.7B 84/100

Frequently Asked Questions

Sarepta Therapeutics,, Inc. (SRPT) reported $2.2B in total revenue for fiscal year 2025. This represents a 15.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Sarepta Therapeutics,, Inc. (SRPT) revenue grew by 15.6% year-over-year, from $1.9B to $2.2B in fiscal year 2025.

No, Sarepta Therapeutics,, Inc. (SRPT) reported a net loss of $114.6M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $713.4M, with a net profit margin of -32.5%.

Sarepta Therapeutics,, Inc. (SRPT) reported diluted earnings per share of -$7.13 for fiscal year 2025. This represents a -404.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sarepta Therapeutics,, Inc. (SRPT) had EBITDA of -$655.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Sarepta Therapeutics,, Inc. (SRPT) had $801.3M in cash and equivalents against $829.0M in long-term debt.

Sarepta Therapeutics,, Inc. (SRPT) had an operating margin of -31.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Sarepta Therapeutics,, Inc. (SRPT) had a net profit margin of -32.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Sarepta Therapeutics,, Inc. (SRPT) has a return on equity of -62.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Sarepta Therapeutics,, Inc. (SRPT) recorded an outflow of $307.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Sarepta Therapeutics,, Inc. (SRPT) recorded an outflow of $205.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Sarepta Therapeutics,, Inc. (SRPT) had $3.3B in total assets as of fiscal year 2025, including both current and long-term assets.

Sarepta Therapeutics,, Inc. (SRPT) invested $102.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Sarepta Therapeutics,, Inc. (SRPT) invested $1.5B in research and development during fiscal year 2025.

Yes, Sarepta Therapeutics,, Inc. (SRPT) spent $25.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Sarepta Therapeutics,, Inc. (SRPT) had 105M shares outstanding as of fiscal year 2025.

Sarepta Therapeutics,, Inc. (SRPT) had a current ratio of 2.32 as of fiscal year 2025, which is generally considered healthy.

Sarepta Therapeutics,, Inc. (SRPT) had a debt-to-equity ratio of 0.73 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Sarepta Therapeutics,, Inc. (SRPT) had a liabilities-to-equity ratio of 1.94 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Sarepta Therapeutics,, Inc. (SRPT) had a return on assets of -21.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Sarepta Therapeutics,, Inc. (SRPT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $1.6B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Sarepta Therapeutics,, Inc. (SRPT) trades at 0.8x sales, its market capitalization divided by $2.0B revenue, trailing 12 months to September 30, 2026. The market capitalization is $1.6B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Sarepta Therapeutics,, Inc. (SRPT) held $940.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $205.5M over that year. Dividing the one by the other, the reported balance equals about 55 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Sarepta Therapeutics,, Inc. (SRPT) has an Altman Z-Score of -1.12, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Sarepta Therapeutics,, Inc. (SRPT) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Sarepta Therapeutics,, Inc. (SRPT) reported a net loss of $713.4M while operations used $205.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Sarepta Therapeutics,, Inc. (SRPT) reported an operating loss of $699.8M against $38.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Sarepta Therapeutics,, Inc. (SRPT) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top